Skip to main content

Table 2 Characteristics of patients receiving a second-line treatment for advanced NSCLC in the pre– and post–I-O periods

From: Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

 

PreI-O

(1 January 2010–31 March 2016)

PostI-O

(1 April 2016–30 June 2019)

All (N = 690)a

NSQ (n = 500)

SQ (n = 87)

All (N = 326)b

NSQ (n = 243)

SQ (n = 57)

Age,c years

Median

Q1–Q3

Range

65

57–72

29–91

65

56.5–72.5

29–91

66

62–72

39–80

66

59–73

31–90

65

58–73

31–90

70

64–72

43–84

Female, n (%)

380 (55.1)

296 (59.2)

36 (41.4)

177 (54.3)

148 (60.9)

16 (28.1)

Initial TNM stage, n (%)

I–IIIAd

66 (9.6)

36 (7.2)

17 (19.5)

38 (11.7)

22 (9.1)

15 (26.3)

IIIB

86 (12.5)

59 (11.8)

19 (21.8)

38 (11.7)

21 (8.6)

14 (24.6)

IV

538 (78.0)

405 (81.0)

51 (58.6)

250 (76.7)

200 (82.3)

28 (49.1)

Location of metastases, n (%)

Visceral, excl. adrenal/liver

164 (23.8)

132 (26.4)

12 (13.8)

77 (23.6)

63 (25.9)

9 (15.8)

Bone

94 (13.6)

80 (16.0)

6 (6.9)

50 (15.3)

43 (17.7)

 < 5

Liver

47 (6.8)

35 (7.0)

 < 5

16 (4.9)

13 (5.3)

 < 5

Brain

44 (6.4)

39 (7.8)

 < 5

39 (12.0)

34 (14.0)

 < 5

Lymph

39 (5.7)

26 (5.2)

7 (8.0)

21 (6.4)

15 (6.2)

 < 5

Adrenal

25 (3.6)

17 (3.4)

 < 5

13 (4.0)

13 (5.3)

0 (0.0)

CCI, n (%)

0

234 (33.9)

171 (34.2)

25 (28.7)

108 (33.1)

89 (36.6)

14 (24.6)

1

165 (23.9)

118 (23.6)

30 (34.5)

72 (22.1)

50 (20.6)

19 (33.3)

2

69 (10.0)

47 (9.4)

14 (16.1)

27 (8.3)

18 (7.4)

6 (10.5)

3

91 (13.2)

68 (13.6)

8 (9.2)

39 (12.0)

26 (10.7)

11 (19.3)

4 + 

131 (19.0)

96 (19.2)

10 (11.5)

80 (24.5)

60 (24.7)

7 (12.3)

First-line treatment, n (%)

Platinum-based chemotherapy

491 (71.2)

331 (66.2)

77 (88.5)

189 (58.0)

123 (50.6)

46 (80.7)

Tyrosine kinase inhibitor

154 (22.3)

141 (28.2)

 < 5

104 (31.9)

100 (41.2)

 < 5

Non-platinum chemotherapy

38 (5.5)

23 (4.6)

7 (8.0)

5 (1.5)

 < 5

 < 5

I-O therapy

 < 5

 < 5

0 (0.0)

27 (8.3)

16 (6.6)

7 (12.3)

Other monoclonal antibodies

6 (0.9)

 < 5

 < 5

 < 5

0 (0.0)

 < 5

Duration of first-line treatment, n (%)

 < 1 month

136 (19.7)

78 (15.6)

27 (31.0)

41 (12.6)

20 (8.2)

15 (26.3)

1– < 3 months

328 (47.5)

228 (45.6)

54 (62.1)

132 (40.5)

90 (37.0)

34 (59.6)

3– < 6 months

103 (14.9)

84 (16.8)

 < 5

71 (21.8)

60 (24.7)

6 (10.5)

6– < 12 months

61 (8.8)

53 (10.6)

 < 5

49 (15.0)

44 (18.1)

 < 5

 ≥ 12 months

62 (9.0)

57 (11.4)

 < 5

32 (9.8)

28 (11.5)

 < 5

Unknown

0 (0.0)

0 (0.0)

0 (0.0)

 < 5

 < 5

0 (0.0)

  1. Unless otherwise indicated, all characteristics were recorded at time of diagnosis. Data were masked when patient numbers for an individual category were greater than zero but less than 5
  2. Abbreviations: CCI Charlson Comorbidity Index; I-O immuno-oncology; NOS not otherwise specified; NSCLC non-small cell lung cancer; NSQ non-squamous; Q quartile; SQ squamous; TNM tumor, nodes, metastasis
  3. aPatients had NSQ (n = 500), SQ (n = 87), NOS (n = 93) or Other (n = 10) histology
  4. bPatients had NSQ (n = 243), SQ (n = 57), NOS (n = 25) or Other (n =  < 5) histology
  5. cAge recorded at start of second-line treatment for advanced NSCLC
  6. dPatients with TNM stage I–IIIA NSCLC at diagnosis represent “progressed patients” who subsequently received systemic anticancer therapy during the study period (see Additional file 1)